Conduit Pharmaceuticals approved to transfer listing to Nasdaq Capital Market

Conduit Pharmaceuticals (CDT) announces that, following confirmation of compliance with the Bid Price and Equity Requirements as detailed in the announcement dated May 21, the Company received formal notice from The Nasdaq Stock Market that the Company’s application to transfer the listing of its common stock to The Nasdaq Capital Market has been approved and the Company’s securities will be transferred to The Nasdaq Capital Market at the opening of business on May 23.